Syndax Pharmaceuticals (SNDX) Non-Current Assets (2015 - 2026)

Syndax Pharmaceuticals' Non-Current Assets history runs 12 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 98.38% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $89.6 million, a 64.97% decrease from a year earlier, with the FY2025 full-year figure at $1.6 million, down 98.67% from the prior year.
• Non-Current Assets eased to $1.5 million in Q1 2026 per SNDX's latest filing, from $1.6 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $121.8 million in Q4 2024 and bottomed at $1.5 million in Q1 2026.
• The 5-year median for Non-Current Assets is $18.3 million (2023), against an average of $32.4 million.
• Across the five-year window, Non-Current Assets soared 2707.54% in 2022 and plunged 98.67% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $7.4 million in 2022, then surged by 329.58% to $32.0 million in 2023, then jumped by 280.45% to $121.8 million in 2024, then plunged by 98.67% to $1.6 million in 2025, then fell by 8.25% to $1.5 million in 2026.
• Per Business Quant, the three latest SNDX Non-Current Assets figures stand at $1.5 million (Q1 2026), $1.6 million (Q4 2025), and $22.0 million (Q3 2025).